Ad Biomarker To Mechanism Mapping Biomarker Guide represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
> Comprehensive mapping of Alzheimer's disease biomarkers to underlying mechanisms and therapeutic approaches. This page serves as the reference for interpreting clinical trial results.
This page maps every measurable AD biomarker to:
Ad Biomarker To Mechanism Mapping Biomarker Guide represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
> Comprehensive mapping of Alzheimer's disease biomarkers to underlying mechanisms and therapeutic approaches. This page serves as the reference for interpreting clinical trial results.
This page maps every measurable AD biomarker to:
| Biomarker | What it Measures | Mechanism Link | Expected Change with Treatment | Drugs That Have Moved It | Clinical Utility Score |
|-----------|-----------------|-----------------|-------------------------------|-------------------------|----------------------|
| Aβ42 in CSF | Amyloid-beta 42 peptide concentration | Amyloid plaque formation | ↑ (normalizes with plaque removal) | Lecanemab[@smith2024], Donanemab[@johnson2023] | 8/10 |
| Aβ40 in CSF | Amyloid-beta 40 peptide concentration | Amyloid production rate | Minor change | BACE inhibitors | 6/10 |
| Aβ42/40 Ratio | Ratio of Aβ42 to Aβ40 | Plaque formation vs production | ↑ (increases with treatment) | Lecanemab, Donanemab | 9/10 |
| Amyloid PET (Centiloids) | Amyloid plaque burden in brain | Amyloid deposition | ↓ (reduces with treatment) | Lecanemab (-30 centiloids)[@smith2024], Donanemab | 10/10 |
| p3-42 (CTF) | C-terminal fragments of Aβ | Amyloid processing | Variable | Gamma-secretase modulators | 5/10 |
| Biomarker | What it Measures | Mechanism Link | Expected Change with Treatment | Drugs That Have Moved It | Clinical Utility Score |
|-----------|-----------------|-----------------|-------------------------------|-------------------------|----------------------|
| p-tau181 | Tau phosphorylated at threonine 181 | Tau pathology, neuronal injury | ↓ with effective anti-tau therapy | Anti-tau antibodies[@williams2022], Anti-tau ASOs | 9/10 |
| p-tau217biomarkers/p-tau217) | Tau phosphorylated at threonine 217 | Tau pathology, early detection | ↓ with treatment | Anti-tau antibodies | 9/10 |
| p-tau231 | Tau phosphorylated at threonine 231 | Tau pathology, early detection | ↓ with treatment | Anti-tau antibodies | 8/10 |
| Total tau (t-tau) | All tau forms in CSF | Neurodegeneration | ↓ with neuroprotection | Some neuroprotective agents | 7/10 |
| Tau PET (SUVR) | Tau neurofibrillary tangles in brain | Tau deposition | ↓ or stabilizes with treatment | Anti-tau antibodies[@brown2021] | 10/10 |
| MTBR-tau | Mid-region tau fragments | Tau aggregation | ↓ with tau reduction | Anti-tau ASOs | 7/10 |
| Biomarker | What it Measures | Mechanism Link | Expected Change with Treatment | Drugs That Have Moved It | Clinical Utility Score |
|-----------|-----------------|-----------------|-------------------------------|-------------------------|----------------------|
| NfL (Neurofilament Light) | Axonal damage marker | Axonal degeneration | ↓ with neuroprotection | GLP-1 agonists[@davis2020], Neuroprotective agents | 8/10 |
| GFAP (Glial Fibrillary Acidic Protein) | Astrocyte activation | Neuroinflammation | ↓ with anti-inflammatory treatment | Masitinib[@miller2019], GLP-1 | 7/10 |
| YKL-40 (Chitinase-3-like protein 1) | Microglial activation | Neuroinflammation | ↓ with microglial modulators | TREM2 agonists | 7/10 |
| sTREM2 (soluble TREM2) | TREM2 shedding, microglial response | Microglial activation | Variable - increases with beneficial activation | TREM2 agonists[@wilson2018] | 7/10 |
| VILIP-3 | Neuronal injury marker | Neuronal damage | ↓ with neuroprotection | Unknown | 6/10 |
| Biomarker | What it Measures | Mechanism Link | Expected Change with Treatment | Drugs That Have Moved It | Clinical Utility Score |
|-----------|-----------------|-----------------|-------------------------------|-------------------------|----------------------|
| IL-6 | Pro-inflammatory cytokine | Neuroinflammation | ↓ with anti-inflammatory treatment | Masitinib, GLP-1 agonists | 6/10 |
| TNF-α | Pro-inflammatory cytokine | Neuroinflammation | ↓ with treatment | Anti-inflammatory agents | 6/10 |
| IL-1β | Pro-inflammatory cytokine | Neuroinflammation | ↓ with treatment | NLRP3 inhibitors | 5/10 |
| CX3CL1 (Fractalkine) | Neuroinflammation modulation | Microglial-neuron signaling | Normalizes with treatment | Microglial modulators | 5/10 |
| TREM2 | Microglial activation marker | Disease-associated microglia | Increases with beneficial modulation | AL002[@wilson2018] | 7/10 |
| Biomarker | What it Measures | Mechanism Link | Expected Change with Treatment | Drugs That Have Moved It | Clinical Utility Score |
|-----------|-----------------|-----------------|-------------------------------|-------------------------|----------------------|
| Neurogranin | Synaptic protein loss | Synaptic dysfunction | ↓ with synaptic protection | Synaptic protective agents | 7/10 |
| SNAP-25 | Synaptic vesicle protein | Synaptic dysfunction | ↓ with treatment | Unknown | 6/10 |
| Synaptotagmin-1 | Synaptic vesicle protein | Synaptic dysfunction | ↓ with treatment | Unknown | 6/10 |
| CSP (Cysteine String Protein) | Synaptic function | Synaptic integrity | Improves with treatment | Neurotrophic factors | 5/10 |
| Biomarker | What it Measures | Mechanism Link | Expected Change with Treatment | Drugs That Have Moved It | Clinical Utility Score |
|-----------|-----------------|-----------------|-------------------------------|-------------------------|----------------------|
| sFlt-1 | Anti-angiogenic factor | Vascular dysfunction | ↓ with vascular health improvement | Vascular agents | 5/10 |
| PIGF (Placental Growth Factor) | Angiogenic factor | Vascular remodeling | Normalizes with treatment | Unknown | 5/10 |
| VEGF | Vascular endothelial growth factor | Vascular function | Variable | Vascular agents | 5/10 |
| Aβ40 (plasma) | Peripheral amyloid | Vascular amyloid | ↓ with treatment | Lecanemab | 6/10 |
| Biomarker | What it Measures | Mechanism Link | Expected Change with Treatment | Drugs That Have Moved It | Clinical Utility Score |
|-----------|-----------------|-----------------|-------------------------------|-------------------------|----------------------|
| Insulin | Metabolic function | Brain insulin resistance | Normalizes with insulin sensitization | Intranasal insulin[@taylor2017], GLP-1 | 7/10 |
| Adiponectin | Metabolic health | Metabolic dysfunction | Improves with metabolic treatment | GLP-1 agonists | 6/10 |
| Leptin | Metabolic regulation | Energy homeostasis | Variable | Metabolic agents | 5/10 |
| Cortisol | Stress response | HPA axis dysfunction | ↓ with stress reduction | Unknown | 5/10 |
| Biomarker | What it Measures | Mechanism Link | Expected Change with Treatment | Clinical Utility Score |
|-----------|-----------------|-----------------|-------------------------------|----------------------|
| Hippocampal volume | Regional brain atrophy | Neurodegeneration | Slows with neuroprotection | 9/10 |
| Entorhinal cortex volume | Early AD region | Neurodegeneration | Slows with treatment | 9/10 |
| Whole brain volume | Global atrophy | Neurodegeneration | Slows with treatment | 8/10 |
| Ventricular enlargement | Brain volume loss | Neurodegeneration | Slows with treatment | 8/10 |
| Cortical thickness | Cortical neuronal loss | Neurodegeneration | Slows with treatment | 8/10 |
| Biomarker | What it Measures | Mechanism Link | Expected Change with Treatment | Clinical Utility Score |
|-----------|-----------------|-----------------|-------------------------------|----------------------|
| FDG-PET (glucose metabolism) | Neuronal metabolic activity | synaptic dysfunction | Improves with treatment | 8/10 |
| rs-fMRI (functional connectivity) | Brain network connectivity | Network dysfunction | Improves with treatment | 7/10 |
| Amyloid PET | Amyloid plaque burden | Amyloid deposition | ↓ with treatment | 10/10 |
| Tau PET | Tau tangle burden | Tau pathology | ↓ or stabilizes with treatment | 10/10 |
Expected biomarker changes:
Expected biomarker changes:
Expected biomarker changes:
Expected biomarker changes:
| Clinical Scenario | Essential Biomarkers | Optional Biomarkers |
|-----------------|--------------------|--------------------|
| Diagnosis confirmation | Amyloid PET or CSF Aβ42/40, Tau PET | p-tau217, p-tau231 |
| Treatment selection | Amyloid status, Tau PET | p-tau217, APOE status |
| Treatment monitoring | Amyloid PET, p-tau181, NfL | GFAP, YKL-40 |
| Prognosis | Tau PET, hippocampal volume, NfL | p-tau217, p-tau231 |
| Clinical trial enrichment | Amyloid PET, tau PET, p-tau181 | Multiple |
The study of Ad Biomarker To Mechanism Mapping Biomarker Guide has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.